Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

2024 ASCO® Annual Meeting Insights Hub

H. Hashmi

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

CARTITUDE-4 Update: OS With Cilta-Cel vs. SOC in Len-Refractory Mult…

Maria-Victoria Mateos

Anti-BMCA Bispecific Antibodies - Independent Symposium at the 10th …

Springer Healthcare IME

S. Usmani

When to Consider Bispecific and CAR-T Therapy in MM

SOHO Brazil 2024

N. S. Raje

Multiple Myeloma: Hot Topics in 2024

Yale Cancer Center

S. Browning

Treatment Strategies for R/R MM After Frontline Anti-CD38 Therapy

Integrity CE

S. Usmani, J. Hillengass

Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?

MyCancerHaven

R. Vij, S. Al Hadidi

Highlights in Plasma Cell Disorders From ASCO® and EHA

Insights from 2024 EHA Annual Meeting

S. Al Hadidi

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maintenanc…

2024 ASCO® Annual Meeting Insights Hub

B. Derman

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

H. Hashmi

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Highlights of Recent Updates in Myeloma: Part 2 - R/R Treatment

2024 ASCO® Annual Meeting Insights Hub

A. Jakubowiak

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

The Relapsed and Refractory MM Patient: When Immune Approaches Are I…

Joseph Mikhael

CAR T-Cells in Multiple Myeloma in 2024

Dana-Farber Cancer Institute

A. Sperling

Managing Infectious Complications With Bispecific and CAR-T Therapy …

SOHO Brazil 2024

N. S. Raje

CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…

Samer Al Hadidi